Results of the LATERAL trial presented at the recent ISHLT conference show Medtronic's HVAD can be implanted safely through a thoracotomy procedure instead of the standard sternotomy approach, which is far more invasive. At the same meeting, subset data from the ENDURANCE trial confirms that the sickest heart-failure patients treated with HVAD have similar outcomes as less sick patients, and results of the ENDURANCE Supplement show that blood pressure management minimizes the risk of stroke with HVAD.
Medtronic PLC received two pieces of good news about its HVAD ventricular assist device at the International Society for Heart and Lung Transplantation (ISHLT) Scientific Meeting in San Diego, with encouraging results reported from the LATERAL and ENDURANCE trials.
HVAD, which Medtronic acquired when it bought HeartWare for $1.1bn in August 2016, is approved in Europe as a bridge-to-transplant...